Philippe Conus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5187414/publications.pdf

Version: 2024-02-01

193 papers 7,574 citations

43 h-index 79 g-index

221 all docs

221 docs citations

times ranked

221

7928 citing authors

#	Article	IF	CITATIONS
1	N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia—A Double-Blind, Randomized, Placebo-Controlled Trial. Biological Psychiatry, 2008, 64, 361-368.	0.7	489
2	Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients. Neuropsychopharmacology, 2008, 33, 2187-2199.	2.8	321
3	Impaired glutathione synthesis in schizophrenia: Convergent genetic and functional evidence. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16621-16626.	3.3	275
4	A 600 kb deletion syndrome at 16p11.2 leads to energy imbalance and neuropsychiatric disorders. Journal of Medical Genetics, 2012, 49, 660-668.	1.5	251
5	The Impact of Cannabis Use on Cognitive Functioning in Patients With Schizophrenia: A Meta-analysis of Existing Findings and New Data in a First-Episode Sample. Schizophrenia Bulletin, 2012, 38, 316-330.	2.3	219
6	Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disorders, 2007, 9, 671-678.	1.1	204
7	Defining the Effect of the 16p11.2 Duplication on Cognition, Behavior, and Medical Comorbidities. JAMA Psychiatry, 2016, 73, 20.	6.0	195
8	Developing Psychosis and Its Risk States Through the Lens of Schizotypy. Schizophrenia Bulletin, 2015, 41, S396-S407.	2.3	191
9	Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients. Schizophrenia Research, 2007, 95, 1-8.	1.1	174
10	Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Disorders, 2011, 13, 87-98.	1.1	155
11	Transdiagnostic clinical staging in youth mental health: a first international consensus statement. World Psychiatry, 2020, 19, 233-242.	4.8	153
12	Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. Journal of Psychiatric Research, 2008, 42, 982-990.	1.5	140
13	Is diagnosis enough to guide interventions in mental health? Using case formulation in clinical practice. BMC Medicine, 2012, 10, 111.	2.3	130
14	Diagnostic Stability 18 Months After Treatment Initiation for First-Episode Psychosis. Journal of Clinical Psychiatry, 2005, 66, 1239-1246.	1.1	130
15	Stage managing bipolar disorder. Bipolar Disorders, 2014, 16, 471-477.	1.1	129
16	N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis. Schizophrenia Bulletin, 2018, 44, 317-327.	2.3	121
17	Symptomatic and functional outcome 12 months after a first episode of psychotic mania: barriers to recovery in a catchment area sample. Bipolar Disorders, 2006, 8, 221-231.	1.1	110
18	Pretreatment and Outcome Correlates of Sexual and Physical Trauma in an Epidemiological Cohort of First-Episode Psychosis Patients. Schizophrenia Bulletin, 2010, 36, 1105-1114.	2.3	110

#	Article	IF	Citations
19	Rate and predictors of service disengagement in an epidemiological first-episode psychosis cohort. Schizophrenia Research, 2010, 118, 256-263.	1.1	107
20	The Firstâ€Episode Psychosis Outcome Study: premorbid and baseline characteristics of an epidemiological cohort of 661 firstâ€episode psychosis patients. Microbial Biotechnology, 2007, 1, 191-200.	0.9	100
21	Predictors of Service Disengagement in First-Admitted Adolescents With Psychosis. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 990-999.	0.3	95
22	<scp>T</scp> reatment and <scp>E</scp> arly <scp>I</scp> ntervention in <scp>P</scp> sychosis <scp>P</scp> rogram (<scp>TIPP</scp> â€ <scp>L</scp> ausanne): implementation of an early intervention programme for psychosis in <scp>S</scp> witzerland. Microbial Biotechnology, 2013, 7, 322-328.	0.9	92
23	The proximal prodrome to first episode mania – a new target for early intervention. Bipolar Disorders, 2008, 10, 555-565.	1.1	90
24	First-Episode Mania: A Neglected Priority for Early Intervention. Australian and New Zealand Journal of Psychiatry, 2002, 36, 158-172.	1.3	86
25	Genetic Polymorphism Associated Prefrontal Glutathione and Its Coupling With Brain Glutamate and Peripheral Redox Status in Early Psychosis. Schizophrenia Bulletin, 2016, 42, 1185-1196.	2.3	83
26	Pretreatment and outcome correlates of past sexual and physical trauma in 118 bipolar I disorder patients with a first episode of psychotic mania. Bipolar Disorders, 2010, 12, 244-252.	1.1	79
27	The Number of Genomic Copies at the 16p11.2 Locus Modulates Language, Verbal Memory, and Inhibition. Biological Psychiatry, 2016, 80, 129-139.	0.7	78
28	MMP9/RAGE pathway overactivation mediates redox dysregulation and neuroinflammation, leading to inhibitory/excitatory imbalance: a reverse translation study in schizophrenia patients. Molecular Psychiatry, 2020, 25, 2889-2904.	4.1	76
29	Randomized Controlled Trial of Interventions for Young People at Ultra-High Risk of Psychosis: Study Design and Baseline Characteristics. Australian and New Zealand Journal of Psychiatry, 2009, 43, 818-829.	1.3	74
30	Prevalence and Predictors of Suicide Attempt in an Incidence Cohort of 661 Young People with First-Episode Psychosis. Australian and New Zealand Journal of Psychiatry, 2009, 43, 149-157.	1.3	74
31	An International Society of Bipolar Disorders task force report: Precursors and prodromes of bipolar disorder. Bipolar Disorders, 2019, 21, 720-740.	1.1	71
32	Characterizing the connectome in schizophrenia with diffusion spectrum imaging. Human Brain Mapping, 2015, 36, 354-366.	1.9	70
33	Early intervention in bipolar disorders: opportunities and pitfalls. Medical Journal of Australia, 2007, 187, S11-4.	0.8	68
34	An evidence map of psychosocial interventions for the earliest stages of bipolar disorder. Lancet Psychiatry,the, 2015, 2, 548-563.	3.7	68
35	From neuroprogression to neuroprotection: implications for clinical care. Medical Journal of Australia, 2010, 193, S36-40.	0.8	68
36	Importance of Early Weight Changes to Predict Long-Term Weight Gain During Psychotropic Drug Treatment. Journal of Clinical Psychiatry, 2015, 76, e1417-e1423.	1.1	67

#	Article	IF	Citations
37	Characterisation of the prodrome to a first episode of psychotic mania: Results of a retrospective study. Journal of Affective Disorders, 2010, 124, 341-345.	2.0	66
38	Public health significance of bipolar disorder: implications for early intervention and prevention. Bipolar Disorders, 2014, 16, 548-556.	1.1	64
39	Prevalence, Predictors, and Consequences of Long-Term Refusal of Antipsychotic Treatment in First-Episode Psychosis. Journal of Clinical Psychopharmacology, 2010, 30, 565-572.	0.7	63
40	Motivational Intervention to Reduce Cannabis Use in Young People with Psychosis: A Randomized Controlled Trial. Psychotherapy and Psychosomatics, 2011, 80, 287-297.	4.0	56
41	Genetic Dysregulation of Glutathione Synthesis Predicts Alteration of Plasma Thiol Redox Status in Schizophrenia. Antioxidants and Redox Signaling, 2011, 15, 2003-2010.	2.5	56
42	Quantifying the Effects of 16p11.2 Copy Number Variants on Brain Structure: A Multisite Genetic-First Study. Biological Psychiatry, 2018, 84, 253-264.	0.7	56
43	Quetiapine <i>v.</i> i>lithium in the maintenance phase following a first episode of mania: Randomised controlled trial. British Journal of Psychiatry, 2017, 210, 413-421.	1.7	53
44	Caught in vicious circles: a perspective on dynamic feed-forward loops driving oxidative stress in schizophrenia. Molecular Psychiatry, 2022, 27, 1886-1897.	4.1	53
45	Cannabis use disorder and age at onset of psychosis — A study in first-episode patients. Schizophrenia Research, 2011, 129, 52-56.	1.1	46
46	Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort. Clinical Pharmacokinetics, 2015, 54, 1259-1272.	1.6	44
47	N-acetylcysteine add-on treatment leads to an improvement of fornix white matter integrity in early psychosis: a double-blind randomized placebo-controlled trial. Translational Psychiatry, 2018, 8, 220.	2.4	44
48	Understanding urbanicity: how interdisciplinary methods help to unravel the effects of the city on mental health. Psychological Medicine, 2021, 51, 1099-1110.	2.7	44
49	Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia. JAMA Psychiatry, 2022, 79, 260.	6.0	44
50	Pharmacotherapy of first-episode psychosis. Expert Opinion on Pharmacotherapy, 2003, 4, 717-750.	0.9	43
51	Early Psychosis Prevention and Intervention Centre long-term follow-up study of first-episode psychosis: methodology and baseline characteristics. Microbial Biotechnology, 2007, 1, 49-60.	0.9	42
52	Influence of <i>CRTC1 </i> Polymorphisms on Body Mass Index and Fat Mass in Psychiatric Patients and the General Adult Population. JAMA Psychiatry, 2013, 70, 1011.	6.0	42
53	Mitochondrial, exosomal miR137-COX6A2 and gamma synchrony as biomarkers of parvalbumin interneurons, psychopathology, and neurocognition in schizophrenia. Molecular Psychiatry, 2022, 27, 1192-1204.	4.1	40
54	Schneiderian first rank symptoms predict poor outcome within first episode manic psychosis. Journal of Affective Disorders, 2004, 81, 259-268.	2.0	39

#	Article	IF	CITATIONS
55	Difficult-to-Engage Patients: A Specific Target for Time-Limited Assertive Outreach in a Swiss Setting. Canadian Journal of Psychiatry, 2005, 50, 845-850.	0.9	39
56	Impaired Metabolic Reactivity to Oxidative Stress in Early Psychosis Patients. Schizophrenia Bulletin, 2014, 40, 973-983.	2.3	39
57	Unpacking †the City': An experience-based approach to the role of urban living in psychosis. Health and Place, 2016, 42, 104-110.	1.5	38
58	Pharmacological Treatment in the Early Phase of Bipolar Disorders: What Stage are we at?. Australian and New Zealand Journal of Psychiatry, 2006, 40, 199-207.	1.3	37
59	Mild Depressive Symptoms Mediate the Impact of Childhood Trauma on Long-Term Functional Outcome in Early Psychosis Patients. Schizophrenia Bulletin, 2017, 43, 1027-1035.	2.3	37
60	Redox dysregulation as a link between childhood trauma and psychopathological and neurocognitive profile in patients with early psychosis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12495-12500.	3.3	37
61	Age at the Time of Exposure to Trauma Modulates the Psychopathological Profile in Patients With Early Psychosis. Journal of Clinical Psychiatry, 2016, 77, e612-e618.	1.1	37
62	Psychological needs of adolescents in the early phase of bipolar disorder: implications for early intervention. Microbial Biotechnology, 2011, 5, 100-107.	0.9	34
63	Can a targeted psychological intervention be effective for young people following a first manic episode? Results from an 18â€month pilot study. Microbial Biotechnology, 2012, 6, 380-388.	0.9	34
64	Duration of untreated psychosis: Impact of the definition of treatment onset on its predictive value over three years of treatment. Journal of Psychiatric Research, 2016, 77, 15-21.	1.5	34
65	Duration of untreated psychosis: a proposition regarding treatment definition. Microbial Biotechnology, 2011, 5, 301-308.	0.9	33
66	Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A). Journal of Affective Disorders, 2022, 299, 367-376.	2.0	33
67	Readiness to Participate in Psychiatric Research. Canadian Journal of Psychiatry, 2003, 48, 480-484.	0.9	31
68	Treatment in early psychosis with N-acetyl-cysteine for 6 months improves low-level auditory processing: Pilot study. Schizophrenia Research, 2018, 191, 80-86.	1.1	31
69	Brain connectivity alterations in early psychosis: from clinical to neuroimaging staging. Translational Psychiatry, 2019, 9, 62.	2.4	31
70	Urbanicity: The need for new avenues to explore the link between urban living and psychosis. Microbial Biotechnology, 2020, 14, 398-409.	0.9	31
71	Impulsivity in early psychosis: A complex link with violent behaviour and a target for intervention. European Psychiatry, 2018, 49, 30-36.	0.1	30
72	Cannabis, a Significant Risk Factor for Violent Behavior in the Early Phase Psychosis. Two Patterns of Interaction of Factors Increase the Risk of Violent Behavior: Cannabis Use Disorder and Impulsivity; Cannabis Use Disorder, Lack of Insight and Treatment Adherence. Frontiers in Psychiatry, 2018, 9, 294.	1.3	30

#	Article	IF	CITATIONS
73	Sensorimotor Induction of Auditory Misattribution in Early Psychosis. Schizophrenia Bulletin, 2020, 46, 947-954.	2.3	28
74	Cannabis use in early psychosis is associated with reduced glutamate levels in the prefrontal cortex. Psychopharmacology, 2018, 235, 13-22.	1.5	27
75	N-Acetyl-Cysteine Supplementation Improves Functional Connectivity Within the Cingulate Cortex in Early Psychosis: A Pilot Study. International Journal of Neuropsychopharmacology, 2019, 22, 478-487.	1.0	25
76	Pre-morbid and outcome correlates of first episode mania with psychosis: Is a distinction between schizoaffective and bipolar I disorder valid in the early phase of psychotic disorders?. Journal of Affective Disorders, 2010, 126, 88-95.	2.0	24
77	Pharmacogenetic Study on Risperidone Long-Acting Injection. Journal of Clinical Psychopharmacology, 2013, 33, 289-298.	0.7	24
78	Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial. European Psychiatry, 2015, 30, 975-982.	0.1	24
79	History of offending behavior in first episode psychosis patients: A marker of specific clinical needs and a call for early detection strategies among young offenders. Schizophrenia Research, 2015, 161, 163-168.	1.1	23
80	Rates and predictors of 18-months remission in an epidemiological cohort of 661 patients with first-episode psychosis. Social Psychiatry and Psychiatric Epidemiology, 2017, 52, 1089-1099.	1.6	23
81	Emplacing recovery: how persons diagnosed with psychosis handle stress in cities. Psychosis, 2017, 9, 322-329.	0.4	22
82	Violent behaviour in early psychosis patients: Can we identify clinical risk profiles?. Microbial Biotechnology, 2019, 13, 517-524.	0.9	22
83	The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic. Journal of Affective Disorders, 2022, 299, 393-407.	2.0	22
84	High b-value diffusion-weighted imaging: A sensitive method to reveal white matter differences in schizophrenia. Psychiatry Research - Neuroimaging, 2012, 201, 144-151.	0.9	21
85	Timely N-Acetyl-Cysteine and Environmental Enrichment Rescue Oxidative Stress-Induced Parvalbumin Interneuron Impairments via MMP9/RAGE Pathway: A Translational Approach for Early Intervention in Psychosis. Schizophrenia Bulletin, 2021, 47, 1782-1794.	2.3	21
86	Promotion of Wellbeing for Children of Parents With Mental Illness: A Model Protocol for Research and Intervention. Frontiers in Psychiatry, 2019, 10, 606.	1.3	20
87	Identifying patterns in psychiatric hospital stays with statistical methods: towards a typology of post-deinstitutionalization hospitalization trajectories. Social Psychiatry and Psychiatric Epidemiology, 2019, 54, 1411-1417.	1.6	20
88	Gender differences in first episode psychotic mania. BMC Psychiatry, 2013, 13, 82.	1.1	19
89	Assertive outreach for "difficult to engage―patients: A useful tool for a subgroup of patients in specialized early psychosis intervention programs. Psychiatry Research, 2016, 239, 212-219.	1.7	19
90	Predictors of favourable outcome in young people with a first episode psychosis without antipsychotic medication. Schizophrenia Research, 2017, 185, 130-136.	1.1	19

#	Article	IF	Citations
91	Stable biomarker identification for predicting schizophrenia in the human connectome. NeuroImage: Clinical, 2020, 27, 102316.	1.4	19
92	Internal and Predictive Validity of the French Health of the Nation Outcome Scales: Need for Future Directions. PLoS ONE, 2016, 11, e0160360.	1.1	18
93	Association of CRTC1 polymorphisms with obesity markers in subjects from the general population with lifetime depression. Journal of Affective Disorders, 2016, 198, 43-49.	2.0	18
94	Partialâ€volume modeling reveals reduced gray matter in specific thalamic nuclei early in the time course of psychosis and chronic schizophrenia. Human Brain Mapping, 2020, 41, 4041-4061.	1.9	18
95	A psychoeducation tool for patients with first-episode psychosis. Acta Neuropsychiatrica, 2011, 23, 75-77.	1.0	17
96	Urban remediation: a new recovery-oriented strategy to manage urban stress after first-episode psychosis. Social Psychiatry and Psychiatric Epidemiology, 2020, 55, 273-283.	1.6	17
97	Sudden death among young people with first-episode psychosis: An 8–10year follow-up study. Psychiatry Research, 2010, 177, 305-308.	1.7	16
98	Influence of MCHR2 and MCHR2-AS1 Genetic Polymorphisms on Body Mass Index in Psychiatric Patients and In Population-Based Subjects with Present or Past Atypical Depression. PLoS ONE, 2015, 10, e0139155.	1.1	16
99	Are we missing opportunities for early intervention in bipolar disorder?. Expert Review of Neurotherapeutics, 2012, 12, 5-7.	1.4	15
100	Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia. Journal of Clinical Lipidology, 2018, 12, 219-229.	0.6	15
101	Differentiating schizoaffective and bipolar I disorder in first-episode psychotic mania. Schizophrenia Research, 2012, 140, 31-36.	1.1	14
102	The Swiss Early Psychosis Project SWEPP: a national network. Microbial Biotechnology, 2012, 6, 106-111.	0.9	13
103	Second-Generation Antipsychotics in Adolescent Psychiatric Patients: Metabolic Effects and Impact of an Early Weight Change to Predict Longer Term Weight Gain. Journal of Child and Adolescent Psychopharmacology, 2018, 28, 258-265.	0.7	13
104	Early intervention for bipolar disorder – Do current treatment guidelines provide recommendations for the early stages of the disorder?. Journal of Affective Disorders, 2019, 257, 669-677.	2.0	13
105	Migration in patients with early psychosis: A 3-year prospective follow-up study. Psychiatry Research, 2019, 275, 108-114.	1.7	13
106	The impact of past direct-personal traumatic events on 12-month outcome in first episode psychotic mania: Trauma and early psychotic mania. Australian and New Zealand Journal of Psychiatry, 2014, 48, 1017-1024.	1.3	12
107	Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments. Pharmacogenetics and Genomics, 2015, 25, 246-258.	0.7	12
108	Trajectory and predictors of quality of life in first episode psychotic mania. Journal of Affective Disorders, 2016, 195, 148-155.	2.0	12

#	Article	lF	Citations
109	Early onset of cannabis use and violent behavior in psychosis. European Psychiatry, 2020, 63, e78.	0.1	12
110	Redox Dysregulation and Oxidative Stress in Schizophrenia: Nutrigenetics as a Challenge in Psychiatric Disease Prevention. World Review of Nutrition and Dietetics, 2010, 101, 131-153.	0.1	11
111	Benefits of adjunctive N-acetylcysteine in a sub-group of clozapine-treated individuals diagnosed with schizophrenia. Psychiatry Research, 2015, 230, 982-983.	1.7	11
112	Change in Emotional and Theory of Mind Processing in Borderline Personality Disorder. Journal of Nervous and Mental Disease, 2018, 206, 935-943.	0.5	11
113	Fronto-Temporal Disconnection Within the Presence Hallucination Network in Psychotic Patients With Passivity Experiences. Schizophrenia Bulletin, 2021, 47, 1718-1728.	2.3	11
114	Exploring the clinical relevance of a dichotomy between affective and nonâ€affective psychosis: Results from a firstâ€episode psychosis cohort study. Microbial Biotechnology, 2022, 16, 168-177.	0.9	10
115	Psychological trauma occurring during adolescence is associated with an increased risk of greater waist circumference in Early Psychosis patients treated with psychotropic medication. PLoS ONE, 2020, 15, e0242569.	1.1	10
116	Clozapine is more efficacious for tongue dystonia than olanzapine. Psychopharmacology, 2002, 162, 89-89.	1.5	9
117	Visuospatial Working Memory Deficits and Visual Pursuit Impairments are Not Directly Related in Schizophrenia. Australian and New Zealand Journal of Psychiatry, 2009, 43, 766-774.	1.3	9
118	Prediction of early weight gain during psychotropic treatment using a combinatorial model with clinical and genetic markers. Pharmacogenetics and Genomics, 2016, 26, 547-557.	0.7	9
119	Social and academic premorbid adjustment domains predict different functional outcomes among youth with first episode mania. Journal of Affective Disorders, 2017, 219, 133-140.	2.0	9
120	Prevalence of ECG abnormalities and risk factors for QTc interval prolongation in hospitalized psychiatric patients. Therapeutic Advances in Psychopharmacology, 2019, 9, 204512531989138.	1.2	9
121	Effect of Quetiapine, from Low to High Dose, on Weight and Metabolic Traits: Results from a Prospective Cohort Study. Pharmacopsychiatry, 2021, 54, 279-286.	1.7	9
122	Evidence of mediation of severity of anxiety and depressive symptoms between abuse and positive symptoms of psychosis. Journal of Psychiatric Research, 2022, 150, 353-359.	1.5	9
123	Olanzapineâ€associated doseâ€dependent alterations for weight and metabolic parameters in a prospective cohort. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 531-541.	1.2	9
124	Olanzapine in subjects with a first-episode psychosis non-responsive, intolerant or non-compliant to a first-line trial of risperidone. International Journal of Psychiatry in Clinical Practice, 2005, 9, 244-250.	1.2	8
125	Redox Dysregulation and Oxidative Stress in Schizophrenia: Nutrigenetics as a Challenge in Psychiatric Disease Prevention. Journal of Nutrigenetics and Nutrigenomics, 2010, 3, 267-289.	1.8	8
126	Beyond clinical staging of psychiatric disorders. Lancet Psychiatry, the, 2015, 2, e27.	3.7	8

#	Article	IF	CITATIONS
127	Community Treatment Order: Identifying the need for more evidence based justification of its use in first episode psychosis patients. Schizophrenia Research, 2017, 185, 67-72.	1.1	8
128	Influence of polygenic risk scores on lipid levels and dyslipidemia in a psychiatric population receiving weight gain-inducing psychotropic drugs. Pharmacogenetics and Genomics, 2017, 27, 464-472.	0.7	8
129	Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses. Clinical Pharmacokinetics, 2020, 59, 371-382.	1.6	8
130	Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohort. Translational Psychiatry, 2021, 11, 360.	2.4	8
131	Evaluation of Cardiometabolic Risk in a Large Psychiatric Cohort and Comparison With a Population-Based Sample in Switzerland. Journal of Clinical Psychiatry, 2020, 81, .	1.1	8
132	Association of variants in SH2B1 and RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs. Gene, 2017, 628, 8-15.	1.0	7
133	Insomnia disorders are associated with increased cardiometabolic disturbances and death risks from cardiovascular diseases in psychiatric patients treated with weight-gain-inducing psychotropic drugs: results from a Swiss cohort. BMC Psychiatry, 2022, 22, 342.	1.1	7
134	Familial Psychopathology in the First Episode Psychosis Outcome Study. Australian and New Zealand Journal of Psychiatry, 2008, 42, 617-626.	1.3	6
135	Predictors of substance use reduction in an epidemiological firstâ€episode psychosis cohort. Microbial Biotechnology, 2014, 8, 358-365.	0.9	6
136	The impact of insight in a first-episode mania with psychosis population on outcome at 18 months. Journal of Affective Disorders, 2014, 167, 74-79.	2.0	6
137	The coupling of low-level auditory dysfunction and oxidative stress in psychosis patients. Schizophrenia Research, 2017, 190, 52-59.	1.1	6
138	Moderating role of cannabis use between insight and depression in early psychosis. Schizophrenia Research, 2020, 215, 61-65.	1.1	6
139	A narrative review of intervention in first-episode affective psychoses. Journal of Psychiatric Research, 2021, 143, 123-137.	1.5	6
140	Termination of therapy: what can clinicians do to maximise gains?. Acta Neuropsychiatrica, 2010, 22, 43-45.	1.0	5
141	Association of PCK1 with Body Mass Index and Other Metabolic Features in Patients With Psychotropic Treatments. Journal of Clinical Psychopharmacology, 2015, 35, 544-552.	0.7	5
142	Psychotropic drug-induced genetic-epigenetic modulation of CRTC1 gene is associated with early weight gain in a prospective study of psychiatric patients. Clinical Epigenetics, 2019, 11, 198.	1.8	5
143	Rate and predictors of disengagement in an early psychosis program with time limited intensification of treatment. Journal of Psychiatric Research, 2020, 131, 33-38.	1.5	5
144	White Matter Alterations Between Brain Network Hubs Underlie Processing Speed Impairment in Patients With Schizophrenia. Schizophrenia Bulletin Open, 2021, 2, sgab033.	0.9	5

#	Article	IF	CITATIONS
145	Pharmacological Treatment in the Early Phase of Bipolar Disorders: What Stage are we at?., 0, .		5
146	Daily Dose Effects of Risperidone on Weight and Other Metabolic Parameters. Journal of Clinical Psychiatry, 2022, 83, .	1.1	5
147	Duration of untreated psychosis: What are we talking about?. Acta Neuropsychiatrica, 2009, 21, 106-108.	1.0	4
148	Patients participating to neurobiological research in early psychosis: A selected subgroup?. Schizophrenia Research, 2018, 201, 249-253.	1.1	4
149	City Avoidance in the Early Phase of Psychosis: A Neglected Domain of Assessment and a Potential Target for Recovery Strategies. Frontiers in Psychiatry, 2019, 10, 342.	1.3	4
150	Topology predicts long-term functional outcome in early psychosis. Molecular Psychiatry, 2020, 26, 5335-5346.	4.1	4
151	Health-related quality of life and functioning in bipolar disorder: the impact of pharmacotherapy. Expert Review of Pharmacoeconomics and Outcomes Research, 2006, 6, 509-523.	0.7	3
152	Trauma and psychosis: some aspects of a complex relationship. Acta Neuropsychiatrica, 2009, 21, 148-150.	1.0	3
153	Association of genetic risk scores with body mass index in Swiss psychiatric cohorts. Pharmacogenetics and Genomics, 2016, 26, 208-217.	0.7	3
154	Association Between Plasma Caffeine and Other Methylxanthines and Metabolic Parameters in a Psychiatric Population Treated With Psychotropic Drugs Inducing Metabolic Disturbances. Frontiers in Psychiatry, 2018, 9, 573.	1.3	3
155	â€~ls "early intervention―in bipolar disorder what it claims to be?' Malhi etÂal. Bipolar Disorders, 2018, 20, 181-183.	1.1	3
156	Precision psychiatry: Promises madeâ€"Promises to be kept?. Australian and New Zealand Journal of Psychiatry, 2019, 53, 841-843.	1.3	3
157	Mechanisms of change in brief treatments for borderline personality disorder: a protocol of a randomized controlled trial. Trials, 2020, 21, 335.	0.7	3
158	Valproate is associated with early decrease of highâ€density lipoprotein cholesterol levels in the psychiatric population. Basic and Clinical Pharmacology and Toxicology, 2021, 129, 26-35.	1.2	3
159	A protocol for the first episode psychosis outcome study (<scp>FEPOS</scp>): ≥15 year followâ€up after treatment at the <scp>Early Psychosis Prevention and Intervention Centre, Melbourne, Australia</scp> . Microbial Biotechnology, 2022, 16, 715-723.	0.9	3
160	Lipid Disturbances in Adolescents Treated With Second-Generation Antipsychotics. Journal of Clinical Psychiatry, 2019, 80, .	1.1	3
161	Six months functional response to early psychosis intervention program best predicts outcome after three years. Schizophrenia Research, 2021, 238, 62-69.	1.1	3
162	Encoding dysfunctions in a dynamic–static paradigm for visuospatial working memory in firstâ€episode psychosis patients: a 2â€year followâ€up study. Microbial Biotechnology, 2009, 3, 44-51.	0.9	2

#	Article	IF	Citations
163	Subtyping based on premorbid profile: A strategy to personalize treatment in firstâ€episode affective psychosis. Microbial Biotechnology, 2022, 16, 51-60.	0.9	2
164	Metabolomic alteration induced by psychotropic drugs: Shortâ€term metabolite profile as a predictor of weight gain evolution. Clinical and Translational Science, 2021, 14, 2544-2555.	1.5	2
165	Associations Between High Plasma Methylxanthine Levels, Sleep Disorders and Polygenic Risk Scores of Caffeine Consumption or Sleep Duration in a Swiss Psychiatric Cohort. Frontiers in Psychiatry, 2021, 12, 756403.	1.3	2
166	Caught in vicious circles: a perspective on dynamic feed-forward loops driving oxidative stress in schizophrenia; Response to "Adaptive changes to oxidative stress in schizophrenia by Lena Palaniyappanâ€, Molecular Psychiatry, 2022, 27, 3567-3568.	4.1	2
167	Preventive strategies in bipolar disorders: identifying targets for early intervention., 0,, 223-240.		1
168	T52. N-ACETYL-CYSTEINE ADD-ON TREATMENT LEADS TO AN IMPROVEMENT OF FORNIX WHITE MATTER INTEGRITY IN EARLY PSYCHOSIS. Schizophrenia Bulletin, 2018, 44, S133-S134.	2.3	1
169	Frontal cortical thickness correlates positively with impulsivity in early psychosis male patients. Microbial Biotechnology, 2019, 13, 848-852.	0.9	1
170	Personality disorder among youth with first episode psychotic mania: An important target for specific treatment?. Microbial Biotechnology, 2022, 16, 256-263.	0.9	1
171	Not in education, employment and training status in the early stages of bipolar I disorder with psychotic features. Microbial Biotechnology, 2021, , .	0.9	1
172	Patients', carers' and clinicians' attitudes towards alternative terms to describe the at-risk for psychosis state. Schizophrenia Research, 2021, 237, 69-75.	1.1	1
173	Evolution of impulsivity levels in relation to early cannabis use in violent patients in the early phase of psychosis. Psychological Medicine, 2022, , 1-10.	2.7	1
174	The differential impact of duration of untreated psychosis on functioning and quality of life: A threshold analysis. Microbial Biotechnology, 2023, 17, 354-360.	0.9	1
175	Symptom dimensions stability over time in recent onset psychosis: A prospective study. Schizophrenia Research, 2022, 246, 126-131.	1.1	1
176	PRE-TREATMENT, BASELINE AND TREATMENT CORRELATES OF OUTCOME IN AN EPIDEMIOLOGICAL COHORT OF FIRST EPISODE PSYCHOSIS PATIENTS. Schizophrenia Research, 2010, 117, 282-283.	1.1	0
177	Nonpharmalogical Substances for Early Intervention. Key Issues in Mental Health, 0, , 159-167.	0.6	0
178	M3. Topological Analyses of Metabolomic Data to Identify Markers of Early Psychosis and Disease Biotypes. Schizophrenia Bulletin, 2017, 43, S211-S212.	2.3	0
179	SA58. The First-Episode Psychosis Outcome Study: Preliminary Data on the Long-Term Follow-Up of First-Episode Psychosis Patients Who Were Treated at the Early Psychosis Prevention and Intervention Centre Between 1998 and 2000. Schizophrenia Bulletin, 2017, 43, S134-S134.	2.3	0
180	16.2 CHILDHOOD TRAUMA ENGAGES OXIDATIVE STRESS, HIPPOCAMPUS ALTERATIONS, AND POORER CLINICAL OUTCOME IN EARLY PSYCHOSIS PATIENTS. Schizophrenia Bulletin, 2018, 44, S25-S26.	2.3	0

#	Article	IF	CITATIONS
181	Qui a besoin de suivi intensif dans le milieu dans un programme spécialisé pour les psychoses émergentes�. Annales Medico-Psychologiques, 2018, 176, 74-79.	0.2	O
182	S164. "AT-RISK MENTAL STATES―PROGRAM IN LAUSANNE: INFLUENCE OF RECRUITMENT STRATEGIES ON TRATE OF FALSE POSITIVES. Schizophrenia Bulletin, 2018, 44, S389-S389.	HE 2.3	0
183	10.2 REDOX DYSREGULATION, OLIGODENDROCYTES AND WHITE MATTER ALTERATIONS IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S15-S16.	2.3	0
184	29.3 TOPOLOGICAL ANALYSIS ENABLES PREDICTION OF FUNCTIONAL AND SOCIAL OUTCOMES IN EARLY PSYCHOSIS. Schizophrenia Bulletin, 2019, 45, S137-S137.	2.3	0
185	S69. CLINICAL HIGH RISK STATE: STRATIFICATION BASED ON CLINICAL PROFILE AND REDOX STATUS. Schizophrenia Bulletin, 2020, 46, S60-S60.	2.3	O
186	S143. NEURAL MECHANISMS OF ROBOT-INDUCED HALLUCINATIONS IN HEALTHY PARTICIPANTS AND SYMPTOMATIC HALLUCINATIONS OF NEUROLOGICAL AND PSYCHIATRIC ORIGIN. Schizophrenia Bulletin, 2020, 46, S90-S91.	2.3	0
187	Redox Dysregulation, Myelination Deficit and Dysconnectivity in Schizophrenia: A Translational Study in First Episode Patients and Experimental Models. Biological Psychiatry, 2020, 87, S100.	0.7	0
188	M16. PROFILING GLUTAMATE AND D-SERINE PATHWAYS IN TREATMENT RESISTANT EARLY PSYCHOSIS PATIENTS. Schizophrenia Bulletin, 2020, 46, S139-S139.	2.3	0
189	Video ethnography: introducing a new tool from research to psychiatric practice?. Psychosis, 2021, 13, 24-34.	0.4	0
190	$D\tilde{A}$ @veloppement de l'insight dans les troubles psychotiques : objectif ou strat \tilde{A} @gie th \tilde{A} @rapeutique ?. , 2018, , 300-309.		0
191	Recovering the Capacity to Live outside of a Psychiatric Hospital: Impact of a Specialized Inpatient Program. Psychiatric Quarterly, 2021, 92, 751-759.	1.1	0
192	Mapping personal geographies in psychosis: from space to place. Schizophrenia Bulletin Open, 0, , .	0.9	0
193	Grouping affective psychoses in early intervention: Justification for specific treatment guidelines. Psychiatry Research, 2022, 314, 114690.	1.7	O